Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 04, 2021 16:01 ET | Source: Passage Bio

Passage Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference

PHILADELPHIA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
January 04, 2021 07:00 ET | Source: Passage Bio

Passage Bio Receives FDA Clearance of IND Application for Lead Gene Therapy Candidate PBGM01 for Treatment of Infantile GM1 Gangliosidosis

FDA clearance marks second regulatory authorization for global Phase 1/2 clinical trial, Imagine-1 study, expected to dose first patient in first quarter 2021 PHILADELPHIA, Jan. 04, 2021 (GLOBE...
December 16, 2020 08:00 ET | Source: Passage Bio

Passage Bio Announces Gene Therapy Manufacturing Research and Development Site

- Company invests to build in-house capabilities to support advancement of pipeline - - In combination with dedicated CGMP suite at Catalent, the new laboratory creates foundation for integrated AAV...
December 10, 2020 16:01 ET | Source: Passage Bio

Passage Bio Receives MHRA Clinical Trial Authorization for PBGM01 for Treatment of GM1 Gangliosidosis

- MHRA approval represents first clinical trial authorization for the global PBGM01 clinical trial program - - Patient enrollment in UK clinical study site expected to start in the second quarter of...
December 07, 2020 07:00 ET | Source: Passage Bio

Passage Bio Teams with Catalent to Start CGMP Manufacturing for Lead Gene Therapy Products

PHILADELPHIA and SOMERSET, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic...
November 23, 2020 16:01 ET | Source: Passage Bio

Passage Bio to Present at Piper Sandler 32nd Annual Healthcare Conference

PHILADELPHIA, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
November 11, 2020 16:30 ET | Source: Passage Bio

Passage Bio Highlights University of Pennsylvania’s Gene Therapy Program’s Newly Published Research to Prevent Toxicity Associated with Gene Therapy

PHILADELPHIA, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
November 11, 2020 07:00 ET | Source: Passage Bio

Passage Bio to Participate in Upcoming November Investor Conferences

PHILADELPHIA, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
November 10, 2020 07:00 ET | Source: Passage Bio

Passage Bio Reports Third Quarter 2020 Financial Results and Recent Business Highlights

– Dosing for first patient in PBGM01 Phase 1/2 trial anticipated in 1Q2021; initial safety and biomarker data expected mid-year 2021 –– Phase 1/2 clinical trials for FTD-GRN and Krabbe expected to...
November 09, 2020 07:00 ET | Source: Passage Bio; Invitae

Passage Bio and Invitae Announce Collaboration to Facilitate Genetic Testing to Support Early Diagnosis and Greater Awareness of Clinical Trials for Patients with GM1

PHILADELPHIA, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...